Vo Nam Xuan, Che Uyen Thi Thuc, Ngo Thanh Thi Thanh, Bui Tien Thuy
Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
Faculty of Pharmacy, Le Van Thinh Hospital, Ho Chi Minh City 700000, Vietnam.
Healthcare (Basel). 2023 Sep 8;11(18):2502. doi: 10.3390/healthcare11182502.
Osteoarthritis (OA) is the degeneration of cartilage in joints that results in bones rubbing against each other; it causes uncomfortable symptoms such as pain, swelling, and stiffness and can lead to disability. It usually occurs in the elderly and causes a large medical burden. The aim of this study is to evaluate the cost-effectiveness between the standard treatment for osteoarthritis and standard treatment with added crystalline glucosamine sulfate at various stages. Markov analysis modeling was applied to evaluate the effect of both adding glucosamine compared to standard treatment from a societal perspective during whole patients' lifetimes. Data input was collected from reviews in previous studies. The outcome was measured in quality-adjusted life years (QALYs), and the Incremental Cost-Effectiveness Ratio (ICER) from a societal perspective was applied with 3% and discounted for all costs and outcomes. One-way analysis via the Tornado diagram was performed to investigate the change in factors in the model. In general, adding glucosamine into the standard treatment proved to be more cost-effective compared to the standard treatment. Particularly, the early-stage addition of glucosamine in the treatment was cost-effective compared to the post-stage addition of glucosamine. The addition of supplementing crystalline glucosamine sulfate to the whole regimen at any stage was cost-effective at the willingness-to-pay (WTP) threshold.
骨关节炎（OA）是关节软骨的退化，导致骨头相互摩擦；它会引起疼痛、肿胀和僵硬等不适症状，并可能导致残疾。它通常发生在老年人身上，造成巨大的医疗负担。本研究的目的是评估骨关节炎标准治疗与在不同阶段添加结晶硫酸葡萄糖胺的标准治疗之间的成本效益。应用马尔可夫分析模型从社会角度评估在患者整个生命周期内添加葡萄糖胺与标准治疗相比的效果。数据输入从先前研究的综述中收集。结果以质量调整生命年（QALYs）衡量，从社会角度应用增量成本效益比（ICER），所有成本和结果均按3%进行贴现。通过龙卷风图进行单向分析，以研究模型中因素的变化。总体而言，与标准治疗相比，在标准治疗中添加葡萄糖胺被证明更具成本效益。特别是，与后期添加葡萄糖胺相比，治疗早期添加葡萄糖胺具有成本效益。在任何阶段将结晶硫酸葡萄糖胺添加到整个治疗方案中，在支付意愿（WTP）阈值下都是具有成本效益的。
